Of note, systemic administration of arvanil (a synthetic, non‐pungent, blood–brain‐barrier permeable vanilloid) to mice harboring high‐grade gliomas decreased tumor size and extended survival of the animals, thus suggesting a therapeutic potential for TRPV1 agonists (Stock et al., 2012). Here, TRPV1 is linked to glioma.